button bars forest bayes pooled summary circles
 
deaths (OS)

metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)

versus placebo
pembrolizumab alone vs. placebo 1 certainty unassessable-42%

metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)

versus sunitinib
atezolizumab alone vs. sunitinib 1 -
atezolizumab plus bevacizumab vs. sunitinib 2 certainty unassessable-6%
avelumab plus axitinib vs. sunitinib 1 certainty unassessable-18%
nivolumab plus cabozantinib vs. sunitinib 1 certainty unassessablestatistically conclusive-37%
nivolumab plus ipilimumab vs. sunitinib 3 certainty unassessable-29%
pembrolizumab plus axitinib vs. sunitinib 1 certainty unassessablestatistically conclusive-43%
pembrolizumab plus lenvatinib vs. sunitinib 1 certainty unassessablestatistically conclusive-31%

mRCC - L1 - PDL1 negative metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 negative

versus sunitinib
atezolizumab plus bevacizumab vs. sunitinib 1 -

mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive

versus sunitinib
atezolizumab alone vs. sunitinib 1 -
atezolizumab plus bevacizumab vs. sunitinib 2 certainty unassessable-15%
avelumab plus axitinib vs. sunitinib 1 certainty unassessable-29%

metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)

versus everolimus
nivolumab alone vs. everolimus 1 certainty unassessablestatistically conclusive-25%

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons